Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling

Oncotarget

Volumn 6, Issue 23, 2015, Pages 19592-19604

  Harazono, Yosuke ^a,b   Kho, Dhong Hyo ^a   Balan, Vitaly ^c   Nakajima, Kosei ^a   Hogan, Victor ^a   Raz, Avraham ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c Everon Biosciences   (United States)

Author keywords

Galectin 3; Multidrug resistance; Na+ K+ ATPase; P glycoprotein; Phosphorylation

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); DOXORUBICIN; GALECTIN 3; MULTIDRUG RESISTANCE PROTEIN; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC ANTIBIOTIC; ATP1A1 PROTEIN, HUMAN; GALECTIN-3, HUMAN; PROTEIN BINDING; PROTEIN TYROSINE KINASE;

ARTICLE; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FUNCTIONAL PROTEOMICS; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETIC TRANSFECTION; GENETICS; HELA CELL LINE; MALE; METABOLISM; NEOPLASMS; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; PROCEDURES; PROTEOMICS; RNA INTERFERENCE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; GALECTIN 3; HELA CELLS; HUMANS; MALE; NEOPLASMS; P-GLYCOPROTEINS; PHENOTYPE; PHOSPHORYLATION; PROTEIN BINDING; PROTEOMICS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SODIUM-POTASSIUM-EXCHANGING ATPASE; SRC-FAMILY KINASES; TRANSFECTION;

EID: 84939229708     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4285     Document Type: Article

References (66)

1. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell. 1994; 76:597-598.
2. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert reviews in molecular medicine. 2008; 10:e17.
3. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochimica et biophysica acta. 2006; 1760:616-635.
4. Harazono Y, Nakajima K, Raz A. Why anti-Bcl-2 clinical trials fail: a solution. Cancer metastasis reviews. 2014; 33:285-94.
5. Sherwi N, Merali S, Wong K. Personalizing biomarker strategies in heart failure with galectin-3. Future cardiology. 2012; 8:885-894.
6. Gao P, Simpson JL, Zhang J, Gibson PG. Galectin-3: its role in asthma and potential as an anti-inflammatory target. Respiratory research. 2013; 14:136.
7. Fortuna-Costa A, Gomes AM, Kozlowski EO, Stelling MP, Pavao MS. Extracellular galectin-3 in tumor progression and metastasis. Frontiers in oncology. 2014; 4:138.
8. Newlaczyl AU, Yu LG. Galectin-3-a jack-of-all-trades in cancer. Cancer letters. 2011; 313:123-128.
9. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchett E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000; 6:1389-1393.
10. Lee YJ, Kang SW, Song JK, Park JJ, Bae YD, Lee EY, Lee EB, Song YW. Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity. Clinical and experimental rheumatology. 2007; 25:S41-45.
11. Yilmaz H, Celik HT, Ozdemir O, Kalkan D, Namuslu M, Abusoglu S, Atalay CR, Yigitoglu R. Serum galectin-3 levels in women with PCOS. J Endocrinol Invest. 2014; 37:181-187.
12. Filipe MD, Meijers WC, Rogier van der Velde A, de Boer RA. Galectin-3 and heart failure: Prognosis, prediction & clinical utility. Clinica chimica acta; international journal of clinical chemistry. 2014.
13. Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, Schnitzbauer A, Schaffler A, Aslanidis C, Scholmerich J, Buechler C. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. The Journal of clinical endocrinology and metabolism. 2010; 95:1404-1411.
14. Zhao Q, Barclay M, Hilkens J, Guo X, Barrow H, Rhodes JM, Yu LG. Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Molecular cancer. 2010; 9:154.
15. Hughes RC. 2001; Galectins as modulators of cell adhesion. Biochimie. 83:667-676.
16. Nangia-Makker P, Balan V, Raz A. Regulation of tumor progression by extracellular galectin-3. Cancer microenvironment: official journal of the International Cancer Microenvironment Society. 2008; 1:43-51.
17. Markowska AI, Jefferies KC, Panjwani N. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. The Journal of biological chemistry. 2011; 286:29913-29921.
18. Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H, Kagawa S, Raz A. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer research. 2003; 63:8302-8311.
19. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A, Raz A. Galectin-3, a novel binding partner of beta-catenin. Cancer research. 2004; 64:6363-6367.
20. Funasaka T, Balan V, Raz A, Wong RW. Nucleoporin Nup98 mediates galectin-3 nuclear-cytoplasmic trafficking. Biochemical and biophysical research communications. 2013; 434:155-161.
21. Elad-Sfadia G, Haklai R, Balan E, Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. The Journal of biological chemistry. 2004; 279:34922-34930.
22. Haudek KC, Voss PG, Locascio LE, Wang JL, Patterson RJ. A mechanism for incorporation of galectin-3 into the spliceosome through its association with U1 snRNP. Biochemistry. 2009; 48:7705-7712.
23. Nakajima K, Kho DH, Yanagawa T, Harazono Y, Gao X, Hogan V, Raz A. Galectin-3 Inhibits Osteoblast Differentiation through Notch Signaling. Neoplasia. 2014; 16:939-949.
24. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer research. 1997; 57:5272-5276.
25. Harazono Y, Kho DH, Balan V, Nakajima K, Zhang T, Hogan V, Raz A. Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells. Oncotarget. 2014; 5:9992-10001.
26. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nature reviews. Drug discovery. 2006; 5:219-234.
27. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature reviews. Cancer. 2002; 2:48-58.
28. Hoffmann EK, Lambert IH. Ion channels and transporters in the development of drug resistance in cancer cells. Philosophical transactions of the Royal Society of London. Series, B, Biological sciences. 2014; 369:20130109.
29. Akiyama K, Ohga N, Hida Y, Kawamoto T, Sadamoto Y, Ishikawa S, Maishi N, Akino T, Kondoh M, Matsuda A, Inoue N, Shindoh M, Hida K. Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment. The American journal of pathology. 2012; 180:1283-1293.
30. Wang H, Wang X, Hu R, Yang W, Liao A, Zhao C, Zhang J, Liu Z. Methylation of SFRP5 is related to multidrug resistance in leukemia cells. Cancer gene therapy. 2014; 21:83-89.
31. Gao X, Balan V, Tai G, Raz A. Galectin-3 induces cell migration via a calcium-sensitive MAPK/ERK1/2 pathway. Oncotarget. 2014; 5:2077-2084.
32. Kim TH, Shin YJ, Won A J, Lee BM, Choi WS, Jung JH, Chung HY, Kim HS. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubic. Biochim Biophys. 2014;. Acta184:615-625.
33. de Boer RA, Verweij N, van Veldhuisen DJ, Westra HJ, Bakker SJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Franke L, Mateo Leach I, van der Harst P. A genome-wide association study of circulating galectin-3. PloS one. 2012; 7:e47385.
34. Panayiotidis MI, Bortner CD, Cidlowski JA. On the mechanism of ionic regulation of apoptosis: would the Na+/K+-ATPase please stand up?. Acta physiologica. 2006; 187:205-215.
35. Tian J, Cai T, Yuan Z, Wang H, Liu L, Haas M, Maksimova E, Huang XY, Xie ZJ. Binding of Src to Na+/K+-ATPase forms a functional signaling complex. Molecular biology of the cell. 2006; 17:317-326.
36. Xie Z, Askari A. Na(+)/K(+)-ATPase as a signal transducer. European journal of biochemistry/FEBS. 2002; 269:2434-2439.
37. Haas M, Wang H, Tian J, Xie Z. Src-mediated inter-receptor cross-talk between the Na+/K+-ATPase and the epidermal growth factor receptor relays the signal from ouabain to mitogen-activated protein kinases. The Journal of biological chemistry. 2002; 277:18694-18702.
38. Jackson CL, Dreaden TM, Theobald LK, Tran NM, Beal TL, Eid M, Gao MY, Shirley RB, Stoffel MT, Kumar MV, Mohnen D. Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure. Glycobiology. 2007; 17:805-819.
39. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009; 28:1788-1791.
40. Blanco G, Mercer RW. Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. The American journal of physiology. 1998; 275:F633-650.
41. Kaplan JH. Biochemistry of Na, K-ATPase. Annual review of biochemistry. 2002; 71:511-535.
42. Alevizopoulos K, Calogeropoulou T, Lang F, Stournaras C. 2014; Na+/K+ ATPase inhibitors in cancer. Current drug targets. 15:988-1000.
43. Mijatovic T, Van Quaquebeke E, Delest B, Debeir O, Darro F, Kiss R. Cardiotonic steroids on the road to anti-cancer therapy. Biochimica et biophysica acta. 2007; :32-57.
44. Mijatovic T, Dufrasne F, Kiss R. Na+/K+-ATPase and cancer. Pharm Pat Anal. 2012; 1:91-106.
45. Durlacher CT1, Chow K, Chen XW, He ZX, Zhang X, Yang T, Zhou SF. Targeting Na+/K+-ATPase in cancer treatment. Clin Exp Pharmacol Physiol. 2015;. [Epub ahead of print] doi: 10.1111/1440-168.
46. Burkhardt-Holm P. Lectin histochemistry of rainbow trout (Oncorhynchus mykiss) gill and skin. The Histochemical journal. 1997; 29:893-899.
47. Barkla DH, Whitehead RH, Hayward IP. Effects of cholera toxin on human colon carcinoma cell lines. Pathology. 1992; 24:296-301.
48. Lauf PK, Heiny J, Meller J, Lepera MA, Koikov L, Alter GM, Brown TL, Adragna NC. Canonical Bcl-2 motifs of the Na+/K+ pump revealed by the BH3 mimetic chelerythrine: early signal transducers of apoptosis? Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2013; 31:257-276.
49. Kennedy DJ, Chen Y, Huang W, Viterna J, Liu J, Westfall K, Tian J, Bartlett DJ, Tang WH, Xie Z, Shapiro JI, Silverstein RL. CD36 and Na/K-ATPase-alpha1 form a proinflammatory signaling loop in kidney. Hypertension. 2013; 61:216-224.
50. Serhan MF, Kreydiyyeh SI. Insulin targets the Na(+)/K(+) ATPase in enterocytes via PI3K, PKC, and MAPKS. Journal of receptor and signal transduction research. 2011; 31:299-306.
51. Morrill GA, Kostellow AB, Askari A. Caveolin-Na/K-ATPase interactions: role of transmembrane topology in non-genomic steroid signal transduction. Steroids. 2012; 77:1160-1168.
52. Straube T, von Mach T, Honig E, Greb C, Schneider D, Jacob R. pH-dependent recycling of galectin-3 at the apical membrane of epithelial cells. Traffic. 2013; 14:1014-1027.
53. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer research. 1999; 59:4148-4154.
54. Simpson CD, Mawji IA, Anyiwe K, Williams MA, Wang X, Venugopal AL, Gronda M, Hurren R, Cheng S, Serra S, Beheshti Zavareh R, Datti A, Wrana J.L, Ezzat S, Schimmer A.D. Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. Cancer research. 2009; 69:2739-2747.
55. Li Z, Xie Z. The Na/K-ATPase/Src complex and cardiotonic steroid-activated protein kinase cascades. European Journal of Physiologye. 2009; 457:635-644.
56. Ye Q, Lai F, Banerjee M, Duan Q, Li Z, Si S, Xie ZJ. Expression of mutant a1 Na/K-ATPase defective in conformational transition attenuates Src-mediated. Journal of biological chemistry. 2013; 288:5803-5814.
57. Liang M, Ca T, Tian J, Qu W, Xie ZJ. Functional characterization of Src-interacting Na/K-ATPase using RNA interference assay. Journal of biological chemistry. 2006; 14:19709-19719.
58. Lefranc F, Kiss R. The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia. 2008; 10:198-201.
59. Yoon J, Terada A, Kita H. CD66b regulates adhesion and activation of human eosinophils. Journal of immunology. 2007; 179:8454-8462.
60. Zhang L, Gallup M, Zlock L, Chen YT, Finkbeiner WE, McNamara NA. Pivotal role of MUC1 glycosylation by cigarette smoke in modulating disruption of airway adherens junctions in vitro. Journal of pathology. 2014; 23:60-73.
61. Chambers TC, Pohl J, Glass DB, Kuo JF. Phosphorylation by protein kinase C and cyclic AMP-dependent protein kinase of synthetic peptides derived from the linker region of human P-glycoprotein. The Biochemical journal. 1994; 299:309-315.
62. Brouillard F, Tondelier D, Edelman A, Baudouin-Legros M. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells. Cancer research. 2001; 61:1693-1698.
63. Baudouin-Legros M, Brouillard F, Tondelier D, Hinzpeter A, Edelman A. Effect of ouabain on CFTR gene expression in human Calu-3 cells. The American journal of physiology - cell physiology. 2003; 284:C620-626.
64. Wojtal KA, de Vries E, Hoekstra D, van Ijzendoorn SC. Efficient trafficking of MDR1/P-glycoprotein to apical canalicular plasma membranes in HepG2 cells requires PKA-RIIalpha anchoring and glucosylceramide. Molecular biology of the cell. 2006; 17:3638-3650.
65. Germann UA, Chambers TC, Ambudkar SV, Licht T, Cardarelli CO, Pastan I, Gottesman MM. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. The Journal of biological chemistry. 1996; 271:1708-1716.
66. Mijatovic T, Kiss R. Cardiotonic steroids-mediated Na+/K+-ATPase targeting could circumvent various chemoresistance pathways. Planta medica. 2013; 79:189-198.